These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 15075120

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 10; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 4. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul 10; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

  • 5. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul 10; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Jul 10; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 8. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 10; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 9. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Dec 10; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R.
    Haematologica; 2005 Oct 10; 90(10):1309-14. PubMed ID: 16219566
    [Abstract] [Full Text] [Related]

  • 13. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Oct 10; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 14. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug 10; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E, Christoulas D, Terpos E.
    Br J Haematol; 2011 Sep 10; 154(5):654-6. PubMed ID: 21615376
    [No Abstract] [Full Text] [Related]

  • 19. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
    Tourkantoni N, Athanassiou-Metaxa M, Zafiriou D, Tzimouli V, Economou M, Taparkou A, Perifanis V, Kanakoudi-Tsakalidou F.
    Hemoglobin; 2008 Sep 10; 32(1-2):35-40. PubMed ID: 18274981
    [Abstract] [Full Text] [Related]

  • 20. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Sep 10; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.